Shares of microcap Alexza Pharmaceuticals (ALXA -44.5%) implode after the FDA issues a scathing report (.pdf) that says the firm's inhaled antipsychotic drug places some patients at risk for respiratory failure. "It is likely that, even with adequate screening for pulmonary risk factors, some patients will require respiratory support post-dose, and some patients will be at risk for respiratory failure and death."
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs